Annovis Bio Inc Ordinary Shares ANVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Annovis Announces Pricing of $21.0 Million Public Offering
Annovis Announces Launch of Proposed Public Offering
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Annovis to Attend the CTAD 2026 with Three Presentations
Trading Information
- Previous Close Price
- $0.85
- Day Range
- $0.83–0.85
- 52-Week Range
- $0.62–5.50
- Bid/Ask
- $0.85 / $0.86
- Shares Outstanding
- 43.02M
- Market Cap
- $35.76M
- Volume/Avg
- 171,641 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.annovisbio.com
Valuation
Metric | ANVS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ANVS |
|---|---|
Quick Ratio | 2.95 |
Current Ratio | 3.47 |
Interest Coverage | — |
Quick Ratio
ANVS
Profitability
Metric | ANVS |
|---|---|
Return on Assets (Normalized) | −244.42% |
Return on Equity (Normalized) | −507.42% |
Return on Invested Capital (Normalized) | −513.96% |
Return on Assets
ANVS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|PG$^D@g | LOCK|h%!@ | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#%J!%r! | LOCK|H@!M | $98B | |||
| Moderna Inc MRNA | LOCK|myf!kzC | LOCK|L?H | $94B | |||
| argenx SE ADR ARGX | LOCK|!%x<MP | LOCK|Kb | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!%c%g#% | LOCK|g@# | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%<VZt@&< | LOCK|X!tz | $31B | |||
| Incyte Corp INCY | LOCK|j#>>zj | LOCK|SK | $25B | |||
| BioNTech SE ADR BNTX | LOCK|zpKPkJ% | LOCK|^$ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|QbBjF! | LOCK|wD<z | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|mMSJ&y# | LOCK|?$ | $15B |
United States